Alectinib is a medicine used to treat a type of lung cancer that has a change in a gene called ALK. It is taken as a capsule by mouth. It works by blocking a signal that tells the cancer cells to grow.
Every report comes from a Lived member, sent anonymously.
Have you tried Alecensa (Alectinib) for Non-Small Cell Lung Cancer?
Alectinib, sold as Alecensa, is a targeted cancer pill for adults with non-small cell lung cancer (NSCLC, the most common kind of lung cancer) whose tumor carries a change in the anaplastic lymphoma kinase (ALK) gene. This change drives the tumor's growth, and such cancers are called ALK-positive. Alectinib only helps when that change is present, so treatment starts with a test approved by the US Food and Drug Administration (FDA) of tumor tissue or, for advanced cancer, sometimes a blood sample. It has two approved uses. After surgery removes an ALK-positive lung tumor that was 4 centimeters or larger or had reached nearby lymph nodes, alectinib is taken for two years to lower the chance of the cancer coming back. This is called adjuvant treatment. For ALK-positive lung cancer that has spread to other parts of the body (metastatic cancer), it is taken for as long as it keeps the cancer in check and side effects stay manageable. Other ALK-targeted pills, such as Alunbrig (brigatinib) and Lorbrena (lorlatinib), are also approved for metastatic disease, and the oncologist weighs these options with each person. Alectinib's safety and effectiveness in children have not been established.
In ALK-positive lung cancer, part of the ALK gene has fused with another gene. The resulting ALK protein is stuck in the on position, sending a constant signal that tells cancer cells to keep growing and dividing. Alectinib is a tyrosine kinase inhibitor: it blocks the ALK protein's signaling activity, which cuts off that growth signal and leaves the cancer cells less able to survive. Alectinib is also active against cancer that has spread to the brain, a common site for ALK-positive lung cancer. In the main trial in people with newly diagnosed advanced disease, the brain was the first place the cancer worsened in 12% of people on alectinib, compared with 45% on crizotinib, an older ALK-targeted drug.
Alecensa comes as 150 mg capsules. The usual adult dose is 600 mg (four capsules) twice a day, taken with food. Swallow the capsules whole; do not open them or dissolve what is inside. If a dose is missed, or if vomiting happens after a dose, skip it and take the next dose at the usual time rather than taking extra. After surgery, treatment lasts two years in total unless the cancer returns or side effects become too difficult. For metastatic cancer there is no fixed end date. Side effects are often handled by pausing the medicine and restarting at a lower dose (450 mg and then 300 mg twice a day); about a quarter of people in the post-surgery trial needed a dose reduction. People with severe liver impairment are started on a lower dose.
The most common side effects are constipation, tiredness, muscle aches, swelling (often in the legs, feet or face), rash and cough. Changes in liver blood tests are also common, which is why testing is frequent early on. Some people notice weight gain, changes in taste, mouth sores, blurred or double vision, or that they sunburn more easily. A few problems need a call to the care team right away rather than waiting for the next appointment. Yellowing of the skin or eyes, dark urine, itching or pain under the right ribs can signal liver injury or, less often, a breakdown of red blood cells (hemolytic anemia). New or worsening shortness of breath, cough or fever can mean lung inflammation (pneumonitis), which can look like the cancer itself and is uncommon but serious. Dizziness, lightheadedness or fainting can come from a very slow heart rate. Less urine than usual or a change in its color can point to kidney injury, which has rarely been fatal. Unexplained muscle pain, tenderness or weakness can reflect muscle damage. Upper abdominal pain with nausea, vomiting or fever can be pancreatitis, an inflammation of the pancreas linked to very high blood fats.
Studies found that common drugs which change how the liver processes many medicines did not meaningfully change alectinib levels. The interaction that matters most is with heart rate: alectinib can slow the heartbeat, so the care team needs to know about any heart or blood pressure medicines, especially ones that also slow the heart. Share a full list of prescriptions, over-the-counter medicines and supplements before starting, and mention any liver disease, lung problems other than the cancer, or a known slow heartbeat. Alectinib can harm a developing baby. People who can become pregnant have a pregnancy test before starting and use effective birth control during treatment and for 5 weeks after the last dose. Men with partners who could become pregnant use birth control during treatment and for 3 months after. A known or suspected pregnancy should be reported to the care team right away. Breastfeeding is not recommended during treatment or for 1 week after the last dose. Alectinib makes skin more sensitive to sunlight. Avoid long stretches in the sun during treatment and for at least 7 days after stopping, and use a broad-spectrum sunscreen and lip balm with a sun protection factor (SPF) of 50 or higher.
Blood tests are a regular part of treatment. Liver tests are done every 2 weeks for the first 3 months, when most liver changes appear, and then monthly. Creatine phosphokinase (CPK), an enzyme released by damaged muscle, is checked every 2 weeks during the first month and whenever muscle symptoms appear. Triglycerides (blood fats) are measured before starting and periodically after, and heart rate and blood pressure are checked at visits. Scans track how the cancer is responding. Finding a problem on these tests usually means a pause or a dose change rather than the end of treatment. For metastatic cancer, the main trial compared alectinib with crizotinib in people who had not yet had ALK-targeted treatment. Tumors shrank in 79% of people taking alectinib, and the cancer was held in check for a median of about 26 months, compared with about 10 months on crizotinib. A median means half of people did better and half did worse, and individual results vary widely. If the cancer grows despite treatment, the oncologist will discuss what comes next. After surgery, a trial compared two years of alectinib with standard chemotherapy. During follow-up, the cancer returned or the person died in 12% of the alectinib group versus 39% of the chemotherapy group. Whether alectinib helps people live longer in this setting was not yet known when those results were reported.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Alecensa (Alectinib), what you've noticed, or ask the community a question.